Article ID Journal Published Year Pages File Type
5902266 Journal of Diabetes and its Complications 2015 8 Pages PDF
Abstract

AimsDemonstrate superiority of insulin glargine (± glulisine) strategy versus premixed insulin strategy for percentage of patients reaching HbA1c < 7% (< 53 mmol/mol) at study end without any documented symptomatic hypoglycemia (bloof glucose [BG] ≤ 3.1 mmol/L) in type 2 diabetes (T2DM) patients failing oral agents.MethodsThis 24-week, open-label, multinational trial randomized patients to glargine OD or premix OD or BID, continuing metformin ± insulin secretagogue (IS). Second premix injection could be added any time; glulisine could be added with main meal in glargine OD patients with HbA1c ≥ 7% and fasting blood glucose (FBG) < 7 mmol/L at week 12. IS was stopped with any second injection. Insulin titration targeted FBG ≤ 5.6 mmol/L.ResultsModified intent-to-treat population comprised 923 patients (glargine, 462; premix, 461). Baseline characteristics were similar (mean T2DM duration: 9 years; HbA1c: 8.7% (72 mmol/mol); FBG: 10.4 mmol/L). Primary endpoint was achieved by 33.2% of glargine (± glulisine) and 31.4% of premix patients. Superiority was not demonstrated, but non-inferiority was (pre-specified margin: 25% of premix rate). More patients using premix achieved target (52.6% vs. 43.2%, p = 0.005); symptomatic hypoglycemia was less with glargine (1.17 vs. 2.93 events/patient-year).ConclusionsGlargine (± glulisine) and premix strategies resulted in similar percentages of well-controlled patients without hypoglycemia, with more patients achieving target HbA1c with premix whereas overall symptomatic hypoglycemia was less with glargine.

Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Endocrinology
Authors
, , , , , , , ,